Caris Life Sciences, Inc.
A precision-medicine company that decodes tumors to help doctors choose cancer treatments. Its laboratory tests, sold under the Caris Molecular Intelligence and MI Cancer Seek brand, analyze the DNA, RNA, and proteins of a patient's tumor to match it with therapies. Founder David Halbert launched the company in 2008, inspired by his mother's cancer battle, and built it around the Molecular Profiling Institute he had purchased in Irving, Texas, where it remains headquartered.
Granted 320.1K
Granted 83.2K
Granted 1.6K
Granted 83.2K
Granted 1.6K
Granted 64.0K
Granted 64.0K
Bought 31.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Halbert David DSee Remarks, Director, 10% owner · 2 transactions | — | 365.65M | 320.1K | — | — |
| Brille Brian JSee Remarks, Director · 2 transactions | — | 1.23M | 83.2K | — | — |
| Poste GeorgeDirector · 1 transaction | -11.4% | 1.07M | 1.6K | — | — |
| Spetzler David BaxleyPresident · 2 transactions | +15% | 530.1K | 83.2K | — | — |
| Knowles Jonathan Kenneth CharlesDirector · 1 transaction | +0.5% | 309.0K | 1.6K | — | — |
| Denton John RusselSee Remarks · 2 transactions | +37.5% | 212.5K | 64.0K | — | — |
| Power Luke ThomasSee Remarks · 2 transactions | -5% | 153.8K | 64.0K | — | — |
| Vacirca Jeff LDirector · 1 transaction | +166.7% | 49.7K | — | 31.1K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +31.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.